MedTrace Logo

Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer

NCT07033143 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-06-24

No results posted yet for this study

Summary

Although the immunotherapy combination regimen has shown good data and safety during the perioperative period of gastric cancer, more clinical studies are still needed to explore the treatment regimens, the number of treatment cycles, the screening of beneficiary populations, and the safety assessment of different drug combinations of immunotherapy combination therapy as adjuvant treatment after gastric cancer surgery.

Conditions

  • Gastric Cance

Interventions

DRUG

Adebrelimab+SOX

Adebrelimab: 1200mg, intravenous drip, day 1, 21 days as one cycle, treatment duration is 1 year. SOX: Eight cycles after the operation, intravenous infusion of oxaliplatin at 130 mg/m2. On the first day, oral administration of S-1 at 40-60 mg twice a day. From the first to the 14th day, 21 days constitute one cycle. Enhanced CT examinations of the chest, abdomen and pelvis were conducted every 9-12 weeks in the first year of treatment. Then have a check-up every 24 weeks.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2028-07-31
Completion
2029-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07033143 on ClinicalTrials.gov